Hiii.. a v.happy news for TYPE-1 DIABETICS.
Recently Teplizumab Mab.. [Monoclonal Antibodies] entered the Phase-3 Clinical Trials..
It is targeted at protecting the Remaining BETA cells in the Autoimmune Newly Diagnosed Type 1 diabetics.. most suitably within the period of 1-12 weeks of 1st sign of Type-1 DM or the date of 1st contacting the physician 4 d complaints.
If the PHASE-3 trials give wonderful drugs.. The phrase "PREVENTION IS BETTER THAN CURE" would have this therapy as its most novel Application.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment